KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of Goods SoldCost Of Goods Sold By SegmentEmployee StatisticsGross Margin %Gross Margin By Segment %Gross ProfitGross Profit By SegmentIncome (Loss) Before Income Tax By RegionLong Lived Assets By Geography AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Income (Loss) By SegmentOperating Income (Loss) By Segment AnnualOperating Margin By Segment %Operating Margin By Segment Annual %Opex As A % Of Total Revenue %OPEX SegregationProperty, Plant, And Equipment, NetRevenue By Category AvkareRevenue By Category Avkare AnnualRevenue By Category GenericsRevenue By Category Generics AnnualRevenue By Category SpecialtyRevenue By Category Specialty AnnualRevenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Gross Profit: 2016-2024

Historic Gross Profit for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $1.0 billion.

  • Amneal Pharmaceuticals' Gross Profit rose 1.64% to $274.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 13.89%. This contributed to the annual value of $1.0 billion for FY2024, which is 24.36% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Gross Profit of $1.0 billion as of FY2024, which was up 24.36% from $820.6 million recorded in FY2023.
  • Amneal Pharmaceuticals' Gross Profit's 5-year high stood at $1.0 billion during FY2024, with a 5-year trough of $628.4 million in FY2020.
  • Moreover, its 3-year median value for Gross Profit was $820.6 million (2023), whereas its average is $875.2 million.
  • Data for Amneal Pharmaceuticals' Gross Profit shows a peak YoY skyrocketed of 78.02% (in 2020) over the last 5 years.
  • Over the past 5 years, Amneal Pharmaceuticals' Gross Profit (Yearly) stood at $628.4 million in 2020, then climbed by 22.37% to $769.0 million in 2021, then grew by 2.05% to $784.7 million in 2022, then climbed by 4.57% to $820.6 million in 2023, then increased by 24.36% to $1.0 billion in 2024.